Suven Life Sciences announces today that the grant of one product patent from Hong Kong, two product patents from India and one product patent from USA corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2032, 2030
and 2034 respectively.

The granted claims of the patents include the class of selective H3 and 5-HT6 compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.

''We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,'' says Venkat Jasti, CEO of Suven.

Shares of the company gained Rs 6.25, or 3.28%, to trade at Rs 197.00. The total volume of shares traded was 103,356 at the BSE (11.15 a.m., Thursday).